CSCID (Cosciens Biopharma) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSCID Cosciens Biopharma Inc CSCID
60 GF Score
Price $5.75
GF Value $8.33
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Net Loan?

Net Loan only applies to banks and insurance companies.

CSCID
60GF Score
Cosciens Biopharma Inc CSCID
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cosciens Biopharma (CSCID) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $5.75 is trading 31% below its estimated GF Value™ of $8.33. GuruFocus considers Cosciens Biopharma to be Possible Value Trap.

Key valuation signals for CSCID:

  • Net Loan:
  • GF Value™: $8.33 vs. price of $5.75 (31% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the CSCID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score

Get the complete analysis for CSCID

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.75
Price
$8.33
GF Value